PeptideOS
← Library

BPC-157

Tissue repair peptide

Also known as: Body Protection Compound 157, Pentadecapeptide BPC 157, PL 14736

Tier 3, Preclinical only

Evidence is limited to animal or in-vitro work. No human pharmacokinetics. Any human dose in circulation is extrapolated, and extrapolation across species routinely fails.

Half-life
Not established · animal data

NO ESTABLISHED HUMAN HALF-LIFE. Elimination half-life is under 30 minutes in rats and beagle dogs, with linear kinetics and intramuscular bioavailability of ~14-19% (rats) and ~45-51% (dogs). The only human characterization is a 2-subject intravenous pilot in which plasma levels returned to baseline within 24 hours. Cross-species extrapolation of peptide pharmacokinetics is unreliable, so no human figure is presented here. Any specific human half-life you see quoted elsewhere is not sourced from human data.

Dosing
No established dose

NO ESTABLISHED HUMAN DOSE. Dosing figures circulating online (commonly cited as 200-500 mcg daily) trace to community convention, not to published human dose-finding studies. They are presented nowhere in this app as a recommendation because no defensible source exists.

Regulatory status
Not approved for human use in any major jurisdiction. Placed on the FDA 503A bulk-compounding "Category 2" list (significant safety risks) in 2023. Prohibited in sport by WADA (S0, non-approved substances).
Evidence base
animal only · confidence: unknown

Large volume of rodent literature, much of it from a single research group in Zagreb, with limited independent replication. Human evidence is limited to small pilot studies. Positive animal findings across an unusually broad range of unrelated conditions is itself a reason for caution rather than confidence.

Storage

Lyophilised: Peptides are generally stored frozen or refrigerated and protected from light; no product-specific label exists.

Reconstituted: No manufacturer stability data exists, there is no approved product to have a label.

Safety

Human safety is not established. There are no adequate human trials, no approved manufacturing standard, and therefore no assurance of identity, purity, or sterility in material sold as BPC-157. The FDA flagged it for significant safety risks in the 503A bulk substances review. Absence of reported harm is not evidence of safety when systematic human study has not been done.